Evelo Biosciences, Inc. (NASDAQ:EVLO – Get Free Report) was the recipient of unusually large options trading on Wednesday. Traders bought 1,885 put options on the company. This represents an increase of approximately 1,101% compared to the typical daily volume of 157 put options.
Analyst Upgrades and Downgrades
Separately, TD Cowen reissued a “market perform” rating on shares of Evelo Biosciences in a report on Wednesday, October 18th. One research analyst has rated the stock with a sell rating and four have given a hold rating to the company’s stock. According to MarketBeat, Evelo Biosciences has a consensus rating of “Hold” and an average target price of $63.33.
Institutional Inflows and Outflows
Evelo Biosciences Price Performance
NASDAQ EVLO opened at $0.45 on Thursday. The business has a fifty day moving average price of $2.66 and a two-hundred day moving average price of $4.29. Evelo Biosciences has a fifty-two week low of $0.30 and a fifty-two week high of $48.00. The stock has a market capitalization of $8.43 million, a PE ratio of -0.03 and a beta of 1.81.
Evelo Biosciences (NASDAQ:EVLO – Get Free Report) last released its earnings results on Monday, August 14th. The company reported ($3.55) earnings per share for the quarter, topping the consensus estimate of ($4.33) by $0.78.
Evelo Biosciences Company Profile
Evelo Biosciences, Inc, a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis.
- Five stocks we like better than Evelo Biosciences
- The Role Economic Reports Play in a Successful Investment Strategy
- Buffett’s latest portfolio additions, trims, and cuts in Q3
- Where to Find Earnings Call Transcripts
- 5 reasons TJX Companies will hit new highs in 2024
- How to Use the MarketBeat Stock Split Calculator
- Game-changing news for Ambarella puts the market in reversal
Receive News & Ratings for Evelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.